TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Vitamin D Requirements During Pregnancy
Brief Summary: The purpose of this study is to determine the effectiveness of vitamin D supplementation during pregnancy starting at the beginning of the second trimester. Mothers will be randomized to one of three vitamin D dosing groups: 400, 2,000 or 4,000 international units per day. It is hypothesized that the highest dosing regimen will result in a better vitamin D status of women regardless of their ethnicity or race.


Options:
A: Arm Label: 400 IU Vitamin D3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 400 IU vitamin D3 | Arm Label: 2,000 IU Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 2,000 IU Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 400 IU vitamin D3; Assigned to Arm(s): 400 IU Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 2,000 IU Vitamin D3; Assigned to Arm(s): 2,000 IU Vitamin D3
B: Arm Label: cholecalciferol-400 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: cholecalciferol (vitamin D3), Drug: cholecalciferol | Arm Label: cholecalciferol 2000 IU; Type: EXPERIMENTAL; Interventions: Drug: cholecalciferol (vitamin D3), Drug: cholecalciferol | Arm Label: cholecalciferol 4000 IU; Type: EXPERIMENTAL; Interventions: Drug: cholecalciferol (vitamin D3), Drug: cholecalciferol | Intervention Type: DRUG; Name: cholecalciferol (vitamin D3); Assigned to Arm(s): cholecalciferol 2000 IU, cholecalciferol 4000 IU, cholecalciferol-400 IU | Intervention Type: DRUG; Name: cholecalciferol; Assigned to Arm(s): cholecalciferol 2000 IU, cholecalciferol 4000 IU, cholecalciferol-400 IU
C: Arm Label: Regimen A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Regimen A calcium and iron/folic acid | Arm Label: Regimen B; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Regimen B calcium and iron/folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Regimen A calcium and iron/folic acid; Assigned to Arm(s): Regimen A | Intervention Type: DIETARY_SUPPLEMENT; Name: Regimen B calcium and iron/folic acid; Assigned to Arm(s): Regimen B
D: Arm Label: 200 IU Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 Supplementation | Arm Label: 2000 IU Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 Supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 Supplementation; Assigned to Arm(s): 200 IU Vitamin D3, 2000 IU Vitamin D3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Vitamin D Requirements During Pregnancy
Brief Summary: The purpose of this study is to determine the effectiveness of vitamin D supplementation during pregnancy starting at the beginning of the second trimester. Mothers will be randomized to one of three vitamin D dosing groups: 400, 2,000 or 4,000 international units per day. It is hypothesized that the highest dosing regimen will result in a better vitamin D status of women regardless of their ethnicity or race.


Options:
A: Arm Label: cholecalciferol-400 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: cholecalciferol (vitamin D3), Drug: cholecalciferol | Arm Label: cholecalciferol 2000 IU; Type: EXPERIMENTAL; Interventions: Drug: cholecalciferol (vitamin D3), Drug: cholecalciferol | Arm Label: cholecalciferol 4000 IU; Type: EXPERIMENTAL; Interventions: Drug: cholecalciferol (vitamin D3), Drug: cholecalciferol | Intervention Type: DRUG; Name: cholecalciferol (vitamin D3); Assigned to Arm(s): cholecalciferol 2000 IU, cholecalciferol 4000 IU, cholecalciferol-400 IU | Intervention Type: DRUG; Name: cholecalciferol; Assigned to Arm(s): cholecalciferol 2000 IU, cholecalciferol 4000 IU, cholecalciferol-400 IU
B: Arm Label: Group A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Group B, Group C, Group D, Group E | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Group A
C: Arm Label: 400 IU Vitamin D3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 400 IU vitamin D3 | Arm Label: 2,000 IU Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 2,000 IU Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 400 IU vitamin D3; Assigned to Arm(s): 400 IU Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 2,000 IU Vitamin D3; Assigned to Arm(s): 2,000 IU Vitamin D3
D: Arm Label: Study group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: D Max drops | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: D Max drops; Assigned to Arm(s): Study group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Multicenter Trial of Antibiotic Prophylaxis in Elective Colorectal Surgery: Single-Dose Vs. Three Doses of Second-Generation Cephalosporin
Brief Summary: To determine the optimal prophylactic antibiotics administration method in elective colorectal surgery


Options:
A: Intervention Type: DRUG; Name: MK0826, ertapenem sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: cefotetan; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: gentamicin-collagen sponge dipped in saline | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: gentamicin-collagen sponge dipped in saline; Assigned to Arm(s): 1
C: Intervention Type: DRUG; Name: Cefmetazole (drug); Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: Intra-peritoneal antibiotic lavage; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of a Humanized Anti-IL-5 Monoclonal Antibody (SB-240563) on Asthma Control, Airway Eosinophilia and the Degree to Which Corticosteroid Treatment Can be Reduced to Maintain Control
Brief Summary: The purpose of this study is to determine if treatment with anti-IL-5 antibody has a prednisone-sparing effect in patients with symptomatic eosinophilic bronchitis (with or without asthma).


Options:
A: Intervention Type: DRUG; Name: SB-240563 (Mepolizumab); Assigned to Arm(s): N/A
B: Arm Label: lebrikizumab - highest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - lowest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - middle dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - middle dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - lowest dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - highest dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MEDI-563 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MEDI-563 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Comp. | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: MEDI-563; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: MEDI-563; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Placebo Comp.; Assigned to Arm(s): 4 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 5
D: Arm Label: Mepolizumab IV; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab IV, Drug: SC Placebo | Arm Label: Mepolizumab SC; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab SC, Drug: IV Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV Placebo, Drug: SC Placebo | Intervention Type: DRUG; Name: Mepolizumab IV; Assigned to Arm(s): Mepolizumab IV | Intervention Type: DRUG; Name: Mepolizumab SC; Assigned to Arm(s): Mepolizumab SC | Intervention Type: DRUG; Name: IV Placebo; Assigned to Arm(s): Mepolizumab SC, Placebo | Intervention Type: DRUG; Name: SC Placebo; Assigned to Arm(s): Mepolizumab IV, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of a Humanized Anti-IL-5 Monoclonal Antibody (SB-240563) on Asthma Control, Airway Eosinophilia and the Degree to Which Corticosteroid Treatment Can be Reduced to Maintain Control
Brief Summary: The purpose of this study is to determine if treatment with anti-IL-5 antibody has a prednisone-sparing effect in patients with symptomatic eosinophilic bronchitis (with or without asthma).


Options:
A: Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: SB-240563 (Mepolizumab); Assigned to Arm(s): N/A
C: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Drug: Fluticasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Fluticasone | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): Omalizumab, Placebo
D: Arm Label: OAT + Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Other: Optimized asthma therapy | Arm Label: Optimized Asthma Treatment (OAT); Type: ACTIVE_COMPARATOR; Interventions: Other: Optimized asthma therapy | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): OAT + Omalizumab | Intervention Type: OTHER; Name: Optimized asthma therapy; Assigned to Arm(s): OAT + Omalizumab, Optimized Asthma Treatment (OAT)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo- Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional Uterine Bleeding.
Brief Summary: The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.


Options:
A: Arm Label: novasure; Type: ACTIVE_COMPARATOR; Interventions: Device: NovaSure | Arm Label: thermachoice; Type: OTHER; Interventions: Device: thermachoice | Intervention Type: DEVICE; Name: NovaSure; Assigned to Arm(s): novasure | Intervention Type: DEVICE; Name: thermachoice; Assigned to Arm(s): thermachoice
B: Arm Label: Levonorgestrel Intrauterine System (LNG IUS) 20µg per 24 hours; Type: EXPERIMENTAL; Interventions: Drug: Levonorgestrel IUS (Mirena, BAY86-5028) | Arm Label: Medroxyprogesterone acetate (MPA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Medroxyprogesterone acetate | Intervention Type: DRUG; Name: Levonorgestrel IUS (Mirena, BAY86-5028); Assigned to Arm(s): Levonorgestrel Intrauterine System (LNG IUS) 20µg per 24 hours | Intervention Type: DRUG; Name: Medroxyprogesterone acetate; Assigned to Arm(s): Medroxyprogesterone acetate (MPA)
C: Arm Label: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: PROCEDURE; Name: hysterectomy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: endometrial ablation; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo- Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional Uterine Bleeding.
Brief Summary: The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.


Options:
A: Intervention Type: DRUG; Name: Provera; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination Birth Control pills; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol; Assigned to Arm(s): N/A
C: Arm Label: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dexamethasone for Cardiac Surgery Trial
Brief Summary: This is a multicenter, randomized, double-blind trial, comparing clinical outcomes after the administration of high-dose dexamethasone versus placebo in patients undergoing heart surgery with the use of cardiopulmonary bypass. The primary endpoint is the occurrence of major complications (including all-cause mortality, myocardial infarction, stroke, renal failure, and prolonged mechanical ventilation) in the first 30 days after surgery.


Options:
A: Arm Label: Study (CytoSorb); Type: EXPERIMENTAL; Interventions: Device: CytoSorb | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Corticosteroid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone | Intervention Type: DEVICE; Name: CytoSorb; Assigned to Arm(s): Study (CytoSorb) | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Corticosteroid
B: Arm Label: Ulinastatin; Type: EXPERIMENTAL; Interventions: Drug: Ulinastatin | Arm Label: Tranexamic Acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline Solution | Intervention Type: DRUG; Name: Ulinastatin; Assigned to Arm(s): Ulinastatin | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic Acid | Intervention Type: DRUG; Name: Saline Solution; Assigned to Arm(s): Placebo
C: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone, Placebo
D: Arm Label: Corticosteroid; Type: EXPERIMENTAL; Interventions: Drug: Corticosteroid | Intervention Type: DRUG; Name: Corticosteroid; Assigned to Arm(s): Corticosteroid

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dexamethasone for Cardiac Surgery Trial
Brief Summary: This is a multicenter, randomized, double-blind trial, comparing clinical outcomes after the administration of high-dose dexamethasone versus placebo in patients undergoing heart surgery with the use of cardiopulmonary bypass. The primary endpoint is the occurrence of major complications (including all-cause mortality, myocardial infarction, stroke, renal failure, and prolonged mechanical ventilation) in the first 30 days after surgery.


Options:
A: Arm Label: methylprednisolone; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): methylprednisolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone, Placebo
C: Arm Label: BIS Monitor guided algorithm; Type: EXPERIMENTAL; Interventions: Device: BIS Monitor guided algorithm | Arm Label: Volatile anesthetic guided algorithm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Volatile anesthetic guided algorithm | Intervention Type: DEVICE; Name: BIS Monitor guided algorithm; Assigned to Arm(s): BIS Monitor guided algorithm | Intervention Type: BEHAVIORAL; Name: Volatile anesthetic guided algorithm; Assigned to Arm(s): Volatile anesthetic guided algorithm
D: Arm Label: Investigational medicinal product; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): Investigational medicinal product | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dexamethasone for Cardiac Surgery Trial
Brief Summary: This is a multicenter, randomized, double-blind trial, comparing clinical outcomes after the administration of high-dose dexamethasone versus placebo in patients undergoing heart surgery with the use of cardiopulmonary bypass. The primary endpoint is the occurrence of major complications (including all-cause mortality, myocardial infarction, stroke, renal failure, and prolonged mechanical ventilation) in the first 30 days after surgery.


Options:
A: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone, Placebo
B: Arm Label: Ketamine arm; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo arm
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 Polyunsaturated Fatty Acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Polyunsaturated Fatty Acid; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Hydrocortisone injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocortisone | Arm Label: normal saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: normal saline 0.9% | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone injection | Intervention Type: DRUG; Name: normal saline 0.9%; Assigned to Arm(s): normal saline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate Safety, Immunogenicity and Efficacy of GSK Biologicals HPV-16/18 L1/AS04 Vaccine Administered Intramuscularly According to a Three-dose Schedule (0, 1, 6 Month) in Healthy Adult Female Subjects Aged 26 Years and Above
Brief Summary: This is a multicentre study in which women were planned to receive either the Human Papillomavirus Vaccine (HPV) vaccine or control. Under Protocol Amendment 3, study participation will last approximately 48 months and involves a total of eleven scheduled visits. Under Protocol Amendment 4, study participation will last up to 84 months and involves a maximum of seventeen scheduled visits.


Options:
A: N/A
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: Aluminium Hydroxide Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo control | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Placebo control; Assigned to Arm(s): Aluminium Hydroxide Group
C: Arm Label: Low-dose V503; Type: EXPERIMENTAL; Interventions: Biological: Experimental: V503 | Arm Label: Mid-dose V503; Type: EXPERIMENTAL; Interventions: Biological: Experimental: V503 | Arm Label: High-dose V503; Type: EXPERIMENTAL; Interventions: Biological: Experimental: V503 | Arm Label: Gardasil; Type: ACTIVE_COMPARATOR; Interventions: Biological: Comparator: GARDASIL, Biological: Experimental: V503 | Intervention Type: BIOLOGICAL; Name: Comparator: GARDASIL; Assigned to Arm(s): Gardasil | Intervention Type: BIOLOGICAL; Name: Experimental: V503; Assigned to Arm(s): Gardasil, High-dose V503, Low-dose V503, Mid-dose V503
D: Arm Label: V503; Type: EXPERIMENTAL; Interventions: Biological: V503 | Arm Label: GARDASIL; Type: ACTIVE_COMPARATOR; Interventions: Biological: GARDASIL | Intervention Type: BIOLOGICAL; Name: V503; Assigned to Arm(s): V503 | Intervention Type: BIOLOGICAL; Name: GARDASIL; Assigned to Arm(s): GARDASIL

Answer: B